Entest BioMedical's ImenVax(TM) Cancer Vaccine Appears to Slow Tumor Growth in Advanced Canine Cancer Cases Without Hazardous Side Effects
SAN DIEGO, CA, Sep 06 (Marketwire) --
Entest BioMedical Inc. (OTCQB: ENTB) a company focused on veterinary
biotechnology and veterinary hospital acquisition / operation, announced
today that the company's recent research study conducted on ImenVax(TM)
(Entest's Immuno-therapeutic cancer vaccine for dogs), ImenVax(TM)
appears to show signs of slowing tumor growth in advanced cases of oral
melanoma, while being well tolerated by patients.
"Principal investigators conducting the safety study on ImenVax(TM)
observed the implantation device and vaccine to be very well-tolerated,"
stated Entest BioMedical Chairman & CEO David Koos. "There was only one
case where the patient had a minor skin irritation. In all of the cases
studied the size of the tumors were likely too extensive to allow for
objective response with ImenVax(TM) as single agent therapy. The
company's researchers stated that subjectively, tumor progression was
slowed during the period that the implant was present and accelerated
after removal in 2 patients. The report recommends that further
evaluation in patients with lesser tumor burden is warranted, along with
cytokine stimulation."
Dr. Koos continued, "Our ImenVax(TM) immune-therapeutic cancer vaccine is
designed to treat dogs with oral melanoma while limiting the side effects
of treatment. We anticipate that within the next 16 months, we will have
the capacity to treat just over 3,000 patients yearly throughout our
veterinary clinics."
A Spokesperson for the Company noted the National Canine Cancer
Foundation says one in three dogs will be impacted by cancer. This
staggering statistic shows not only the need for a cost effective
treatment but also a treatment that is well tolerated. The potential
revenue generated per patient is approximately $3,000 according to
industry statistics. Management indicates that each veterinary hospital
Entest will seek to acquire over the next two years will have a
preexisting patient flow of at least 700 cancer patients per year. Once
the first 10 veterinary hospitals have been acquired, Entest could
possibly see 7,000 treatable canine patients per year at $3,000 per
patient. This meaning, should Entest be successful in meeting its
veterinary hospital acquisition target numbers [10 facilities], the
company could potentially command revenues reflecting as much as $21
million per annum; treating dogs with cancer.
Dr. Koos concluded, "Our ImenVax(TM) immuno-therapeutic cancer vaccine is
being designed to utilize the patient's own immune system to battle the
cancer; potentially making it a less invasive and less traumatic
alternative for pet owners than chemotherapy and radiation therapy. Also,
the safety study is being conducted on dogs suffering from oral melanoma.
We have no intention to simply stop at oral melanoma applications. Entest
is working with an incredibly experienced research team in hopes to
increase efficacy in extreme cases by the inclusion of cytokine
stimulation. We anticipate at some point in the near future, to begin
clinical trials as we will ultimately seek USDA or FDA approval to
further the reach of our ImenVax(TM) canine cancer treatment."
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCQB: ENTB) is a developer of veterinary
medicines that harness the animal's own reparative / immunological
mechanisms. The company's products include an immuno-therapeutic cancer
vaccine for canines (ImenVax(TM)). The company's immuno-therapeutic
cancer vaccine utilizes an encapsulation device as the vaccine delivery
system and requires a simple implant procedure.
Disclaimer
This news release may contain forward-looking statements. Forward-looking
statements are inherently subject to risks and uncertainties, some of
which cannot be predicted or quantified. Future events and actual results
could differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and uncertainties to
which forward-looking statements are subject include, but are not limited
to, the effect of government regulation, competition and other material
risks.
Contact:
Entest BioMedical Inc.
David R. Koos
Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax
info@EntestBio.com
www.EntestBio.com
Copyright 2012, Marketwire, All rights reserved.
"Patience, persistence and perspiration make an unbeatable combination for success."
